

IN THE CLAIMS:

Claims 12-14 are cancelled herein. Claims 22-24 have been added. Claims 1, 9-11, and 15 have been amended herein. All of the pending claims 1 through 11 and 15 through 24 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Currently Amended) A method for reducing cellular damage in tissue that has suffered from or is suffering from hypoxia and/or ischemia and/or inflammation in an individual, said method comprising administering to the individual a therapeutically relevant dose of IFN type-I or a functional part, derivative and/or analogue thereof.

2. (Original) The method according to claim 1, wherein the H/I related inflammation results from a shortage in blood supply.

3. (Original) The method according to claim 1, wherein the H/I related inflammation is restricted to a body part of the individual.

4. (Original) The method according to claim 2, wherein the H/I related inflammation is restricted to a body part of the individual.

5. (Original) The method according to claim 3 or claim 4, wherein the body part comprises the brain, the spinal cord, the heart, a transplanted organ, and/or a limb.

6. (Original) The method according to claim 5, wherein the H/I related inflammation is restricted to a part of the brain, heart or brain and heart.

7. (Original) The method according to claim 6, wherein the H/I related inflammation is restricted to a part of the brain.

8. (Original) The method according to claim 1, claim 2, claim 3, claim 4, claim 5, claim 6, or claim 7, wherein the H/I related inflammation is induced by an obstruction of a blood vessel.

9. (Currently Amended) A method for treating an H/I related inflammation in an individual having at least one blood vessel obstruction causing ischemia in tissue that is situated downstream from said obstruction, said method comprising:

administering to the individual a therapeutically relevant dose of IFN type-I or a functional part, derivative and/or analogue thereof.

10. (Currently Amended) A method for at least in part improving blood flow in ~~post-ischaemic~~ post-ischemic tissue, said method comprising administering, to an individual having said tissue, therapeutically relevant IFN type-I or a functional part, derivative and/or analogue thereof.

11. (Currently Amended) A method for ~~at least in part~~ preventing cell death in ~~post-ischaemic~~ post-ischemic tissue, said method comprising administering, to an individual having said tissue, therapeutically relevant IFN type-I or a functional part, derivative and/or analogue thereof.

12-14. (Cancelled)

15. (Currently Amended) A method for treating a hypoxia/ischemia (H/I) related inflammation in an individual, said method comprising:

administering, to the individual, therapeutically relevant IFN type-I or a functional part, derivative and/or analogue thereof.

16. (Original) The method according to claim 15, wherein the H/I related inflammation results from a shortage in blood supply.

17. (Original) The method according to claim 15 or claim 16, wherein the H/I related inflammation is restricted to a body part of the individual.

18. (Original) The method according to claim 17, wherein the body part comprises the brain, the spinal cord, the heart, a transplanted organ, and/or a limb.

19. (Original) The method according to claim 18, wherein the H/I related inflammation is restricted to a part of the brain, heart, or brain and heart.

20. (Original) The method according to claim 19, wherein the H/I related inflammation is restricted to a part of the brain.

21. (Original) The method according to claim 15, claim 16, claim 17, claim 18, claim 19, and claim 20, wherein the H/I related inflammation is induced by an obstruction of a blood vessel.

22. (New) A method for reducing cellular damage in tissue that has suffered from or is suffering from hypoxia and/or ischaemia and/or inflammation in an individual, said method comprising:

identifying hypoxia and/or ischaemia and/or inflammation in the individual; and

administering to the individual a therapeutically relevant dose of IFN type-I or a functional part, derivative and/or analogue thereof.

23. (New) The method of claim 22, further comprising measuring the change in hypoxia and/or ischaemia and/or inflammation in the individual.

24. (New) The method of claim 23, where the measuring is accomplished via an outcome marker that is correlated with hypoxia and/or ischaemia and/or inflammation in the individual.